BridgeMD
New treatment option for Blood Loss Anemia
Official title Red Blood Cell Transfusion in ECMO - A Feasibility Trial
ClinicalTrials.gov ID: NCT05814094
What this study is testing
- What it's testing
- Extracorporeal Membrane Oxygenation (ECMO) is an invasive and resource intense treatment used to support critically ill patients who have suffered severe cardiac arrest, cardiac failure or respiratory failure (including severe cases of COVID-19). ECMO acts as a mechanical circulatory support temporarily replacing the function of the heart or lungs by oxygenating blood and removing carbon dioxide, allowing time for these organs to recover.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Patients receiving ECMO
- Age: 18 years or older
You likely can't join if
- Contraindication to RBC transfusion (including known patient preference)
- Limitations of care put in place either through patient wishes or the treating medical teams
- ECMO treatment for more than 12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated...
- The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
- Where the treating physician deems the study is not in the patient's best interest
- Where the treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
See the full eligibility criteria
- Patients receiving ECMO
- Age: 18 years or older
- Contraindication to RBC transfusion (including known patient preference)
- Limitations of care put in place either through patient wishes or the treating medical teams
- ECMO treatment for more than 12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start is defined as...
- The treating physician anticipates that ECMO treatment will cease before the end of tomorrow
- Where the treating physician deems the study is not in the patient's best interest
- Where the treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds
- Patients actively listed for a solid organ transplant
- Patients who are suspected or confirmed to be pregnant
- Previous ECMO treatment during the same hospital admission
The study team makes the final eligibility decision.
Where it's taking place
- Camperdown, New South Wales, Australia
- Sydney, New South Wales, Australia
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Camperdown, New South Wales, Australia; Sydney, New South Wales, Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.